On May 16, 2024, the FDA granted a breakthrough therapy designation to NVL-655, a novel brain-penetrant ALK-selective ...

A second poster presentation, titled Development of a second-generation multi-target stool RNA test (ColoSense 2.0) for colorectal cancer screening, demonstrated a preliminary ability to leverage ...

A second poster presentation, titled Development of a second-generation multi-target stool RNA test (ColoSense 2.0) for colorectal cancer screening, demonstrated a preliminary ability to leverage ...

A second poster presentation, titled Development of a second-generation multi-target stool RNA test (ColoSense 2.0) for colorectal cancer screening, demonstrated a preliminary ability to leverage ...

We are highly confident in the strength of our intellectual property. We will continue our efforts to bring ColoSense to market, offering a new screening option for the millions of Americans in need." ...

The new case comes just weeks after the St. Louis company received FDA approval for its own stool-based test to detect ...

We are highly confident in the strength of our intellectual property. We will continue our efforts to bring ColoSense to market, offering a new screening option for the millions of Americans in need." ...

This development, disclosed on Tuesday, allows Exact Sciences to pursue claims regarding the alleged infringement of its patented technology by Geneoscopy's ColoSense test, as well as counter false ...

Company asserts that Geneoscopy will infringe patented technology central to its Cologuard colorectal cancer screening test .

This development, disclosed on Tuesday, allows Exact Sciences to pursue claims regarding the alleged infringement of its patented technology by Geneoscopy's ColoSense test, as well as counter false ...